Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. [electronic resource]
Producer: 20161013Description: e404 p. digitalISSN:- 2044-5385
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- therapeutic use
- Drug Resistance, Neoplasm
- Female
- Follow-Up Studies
- Humans
- Immunoglobulin Heavy Chains -- genetics
- Immunologic Factors -- therapeutic use
- Lenalidomide
- Leukemia, Lymphocytic, Chronic, B-Cell -- diagnosis
- Male
- Middle Aged
- Mutation
- Prognosis
- Recurrence
- Retreatment
- Survival Analysis
- Thalidomide -- analogs & derivatives
- Treatment Outcome
- Tumor Suppressor Protein p53 -- genetics
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.